Arkolith/Insider Trading/AKTS/Form 4

Gadicke Ansbert

10% OwnerAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jan 14, 2026
Net Buying
Open-Market Buys
$20.0M
Open-Market Sells
$0
Net Open-Market Flow
$20.0M
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)1.3M——1.7M
Jan 12, 2026Buy(P)1.1M$18.00$20.0M10.3M
Jan 12, 2026Conversion(C)1.6M——9.1M
Jan 12, 2026Conversion(C)5.9M——7.6M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)6.0M—$00
Jan 12, 2026Conversion(C)5.0M—$00
Jan 12, 2026Conversion(C)22.5M—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001231919-26-000055) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML